Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis

Carbon, Maren, Kane, John M., Leucht, Stefan, Correll, Christoph U.·2018·World Psychiatry
DOI 10.1002/wps.20579

Cited by (213)

Items 101–200 of 213

  1. Historical developments, hotspots, and trends in tardive dyskinesia research: a scientometric analysis of 54 years of publications
    A. Baminiwatta, C. Correll · 2023 · Frontiers in Psychiatry
  2. NEUROPROTECTIVE EFFECT OF METHANOLIC EXTRACT OF SARGASSUM WIGHTII ON HALOPERIDOL INDUCED CATALEPSY AND TARDIVE DYSKINESIA IN ALBINO RATS
    Sradhasini Rout, Bandana Rath, Subrat Kumar Bhattamisra, Anjan Kumar, Sadananda Rath · 2020 · International Journal of Pharmacy and Pharmaceutical Sciences
  3. Ketamine and Esketamine for Treatment-Resistant Depression: Response to Reus, Mattes, and Schatzberg
    Roger S. McIntyre · 2021 · American Journal of Psychiatry
  4. Strategies for Switching between Oral Postsynaptic Antidopaminergic Antipsychotics in Patients with Schizophrenia: A Systematic Review
    Christoph Ulrich Correll · 2025 · CNS Drugs
  5. Tolerability and safety outcomes of first-line oral second-generation antipsychotics in patients with schizophrenia
    Kristen M. Ward, Leslie Citrome · 2024 · Expert Opinion on Drug Safety
  6. A missed case of lurasidone induced laryngospasm: A case study and overview of extrapyramidal symptom identification and treatment
    Deirdre Caffrey, Gillian L. Sowden · 2020 · The International Journal of Psychiatry in Medicine
  7. Regional Homogeneity in schizophrenia patients with tardive dyskinesia: a resting-state fMRI study
    Ting Yue Yu, Yanli Li, Na Li, Junchao Huang, Fengmei Fan, Xingguang Luο, Shuping Tan, Fude Yang, Baopeng Tian, Li Tian et al. · 2023 · Psychiatry Research Neuroimaging
  8. Real-world safety analysis of deutetrabenazine post-marketing: a disproportionality study leveraging the FDA Adverse Event Reporting System (FAERS) database
    Guangwei Qing, Shiyi Ye, Bo Wei, Yuanjian Yang · 2025 · BMC Pharmacology and Toxicology
  9. Choosing among the long-acting injectable antipsychotics: an evidence-based pragmatic guide
    Leslie Citrome · 2025 · CNS Spectrums
  10. Depression, Angststörungen, bipolare Störung, Schizophrenie, Aufmerksamkeitsdefizithyperaktivitätssyndrom
    Johanna Seifert, Stefan Bleich, Roland Seifert · 2022 · Springer eBooks
  11. Genome-wide association study of antipsychotic-induced sinus bradycardia in Chinese schizophrenia patients
    Saizheng Weng, Bo Wang, Mo Li, Shan Chao, Ruiqian Lin, Rongyan Zheng, YU Yin-liang, Shaonan Guo, Xianhao Lin · 2021 · PLoS ONE
  12. Factors shaping the decision-making process to continue or discontinue antipsychotics: exploratory qualitative study of 12 individuals in remission from first-episode psychosis
    Laurent Béchard, Elizabeth Anderson, Olivier Corbeil, Maxime Huot‐Lavoie, Sébastien Brodeur, Amal Abdel‐Baki, Charles Massé, Mina Gabriel-Courval, Marie-Ève Coté, Annie LeBlanc et al. · 2025 · BJPsych Open
  13. Developing STEP‐SE: A Qualitative Usability Study of a Novel Patient‐Reported Outcomes Tool for Managing Side Effects in Shared Decision‐Making for Schizophrenia Spectrum Disorder Care
    Alessandro Rodolico, Antonio Di Francesco, Pierfelice Cutrufelli, Irene Bighelli, Pasquale Caponnetto, Carmen Concerto, Daniela Conti, Rosaria Furnari, Gabriele Leotta, Ludovico Mineo et al. · 2024 · Health Expectations
  14. Plasma Metabolic Characteristics and Potential Biomarker Combinations in Schizophrenia Patients With Tardive Dyskinesia
    Chenghao Lu, Yeqing Dong, Dan Qi, Nannan Liu, Yanzhe Li, Jinghui Chi, Xinxu Wang, Min Zeng, Feng Liu, Shen Li et al. · 2025 · Schizophrenia Bulletin
  15. Substance Abuse Associated with Aggressive/Violent Behaviors in Psychiatric Outpatients and Related Psychotropic Prescription
    Massimo Carlo Mauri, Giovanna Cirnigliaro, Eleonora Piccoli, Matteo E.M. Vismara, Vera De Carlo, Nicolaja Girone, Bernardo Maria Dell’Osso · 2022 · International Journal of Mental Health and Addiction
  16. Tardive Dyskinesia and Dystonia – Clinical Case Review and Grand Rounds
    Satish Suhas, Hariprasad Ganapathy Vijayakumar, Ganesan Venkatasubramanian, Shivarama S. Varambally · 2022 · Journal of Psychiatry Spectrum
  17. Druggable genome-wide Mendelian randomization for identifying the role of integrated stress response in therapeutic targets of bipolar disorder.
    Zhai Ting · 2024 · Journal of Affective Disorders
  18. Measurement-based Diagnosis and Treatment for Tardive Dyskinesia
    Christoph Ulrich Correll, Leslie Citrome · 2021 · The Journal of Clinical Psychiatry
  19. Clozapine's Multiple Cellular Mechanisms: What Do We Know after More than Fifty Years? a Systematic Review and Critical Assessment of Translational Mechanisms Relevant for Innovative Strategies in Treatment-Resistant Schizophrenia
    Andrea de Bartolomeis, Licia Vellucci, Annarita Barone, Mirko Manchia, Vincenzo De Luca, Felice Iasevoli, Christoph Ulrich Correll · 2022 · SSRN Electronic Journal
  20. Updated rationale for the initial antipsychotic selection for patients with schizophrenia
    Matej Markota, Robert J. Morgan, Jonathan G. Leung · 2024 · Schizophrenia
  21. Off-label antipsychotic use patterns among Texas Medicaid adults 2013–2016
    Shuang Chen, Jamie C. Barner, Eun Cho · 2021 · Journal of Comparative Effectiveness Research
  22. A descriptive analysis of spontaneous reports of antipsychotic‐induced tardive dyskinesia and other extrapyramidal symptoms in the Japanese Adverse Drug Event Report database
    Yosuke Saga, Chih‐Lin Chiang, Akihide Wakamatsu · 2023 · Neuropsychopharmacology Reports
  23. Considering New and Emerging Treatment Strategies for Depression: Beyond STAR*D and the Monoamines
    Lynne Alison McInnes, Tobias F. Marton · 2024 · Current Psychiatry Research and Reviews
  24. Analysis of Antipsychotic Dosage in Patients With Tardive Dyskinesia: A Case-Control Study Using the Claims Database of the Corporate Health Insurance Association
    Maki Gouda, Michikazu Abe, Yumi Watanabe, Takahiro A. Kato · 2024 · Journal of Clinical Psychopharmacology
  25. Aripiprazole Augmentation as a Treatment for Clozapine-Induced Weight Gain: Response to Kramer and Velicu
    Roger S. McIntyre, Angela T.H. Kwan, Joshua Daniel Rosenblat, Kayla M. Teopiz, Rodrigo Barbachan Mansur · 2024 · American Journal of Psychiatry
  26. Non–adherence and predictors in patients with schizophrenia on second generation antipsychotics at Amanuel Mental Specialized Hospital, Ethiopia
    Melak Gedamu Beyene, Solomon Teferra, Teferi Gedif Fenta · 2025 · PLoS ONE
  27. Depression, Angststörungen, bipolare Störung, Schizophrenie, Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung
    Johanna Seifert, Stefan Bleich, Roland Seifert · 2025 · Springer eBooks
  28. Reporting Frequency of Antipsychotics‐Induced Tardive Dyskinesia and Other Extrapyramidal Symptoms: Analysis Based on a Spontaneous Reporting System Database in Japan
    Yosuke Saga, Hiroshi Horio, Chih‐Lin Chiang, Akihide Wakamatsu · 2025 · Neuropsychopharmacology Reports
  29. TAAR1-mediated pathways regulating nigrostriatal function and the discovery and pharmacological characterization of a novel TAAR1 agonist, Selutaront
    Jianzhao Zhang, Xuan Deng, Jiawei Lv, Jing Lu, Lin Wang, Wenyan Wang, Hui Lei, Yangping Wang, Jingwei Tian · 2026 · Frontiers in Pharmacology
  30. Clinical Phenotype of Tardive Dyskinesia in Bipolar Disorder
    Manuel Gardea‐Resendez, Monica J. Taylor-Desir, Francisco Romo‐Nava, David J. Bond, Eric J. Vallender, Alfredo B. Cuellar-Barboza, Miguel L. Prieto, Nicolas Nunez, Marin Veldic, Ayşegül Özerdem et al. · 2022 · Journal of Clinical Psychopharmacology
  31. Early onset tardive syndromes associated with Lurasidone in patients with mood disorders: A case series and literature review
    Aditya Nidumolu, Anthony Pianosi, Claire O’Donovan · 2022 · Journal of Affective Disorders Reports
  32. Is preventing the second psychotic episode a disease-modifying strategy for schizophrenia?
    Henry A. Nasrallah · 2023 · Schizophrenia Research
  33. Cannabigerol Mitigates Haloperidol-Induced Vacuous Chewing Movements in Mice
    Rafaela Ponciano, Jaime E. C. Hallak, José Alexandre S. Crippa, Francisco Silveira Guimarães, Elaine Ap. Del Bel · 2024 · Neurotoxicity Research
  34. ¿Es aún válida la división entre antipsicóticos “clásicos” y “atípicos”?
    Santiago Stucchi-Portocarrero · 2019 · Revista de Neuro-Psiquiatría
  35. Ginkgo biloba for Tardive Dyskinesia and Plasma MnSOD Activity: Association with MnSOD Ala-9Val Variant: A Randomized, Double-blind Trial
    Dongmei Wang, Yang Tian, Jiajing Chen, Rongrong Zhu, Jiaxin Li, Huixia Zhou, Dachun Chen, Li Wang, Thomas R. Kosten, Xiangyang Zhang · 2024 · Current Neuropharmacology
  36. Aripiprazole-Induced Orofacial Dyskinesia in a Young Male: A Case Report
    Udai Godhania, Jayaprakash Rajendran, Oluwagbenga Odeyemi · 2024 · Cureus
  37. Tardive Syndromes: A Challenging Multitude of Maladies
    Ranjot Kaur, Vaibhav Bansidhar Patil, Ayush Agarwal, Achal Kumar Srivastava, Divyani Garg · 2025 · Annals of Indian Academy of Neurology
  38. Synopsis of Chemical and Drug-Related Agents That Cause Movement Disorders
    Şükrü Alperen Korkmaz · 2025 · Springer eBooks
  39. Real-World Claims Analysis to Characterize the Burden of Tardive Dyskinesia in Long-Term Care Settings
    Morgan Bron, Gideon N. Aweh, Eric Jen, Amita Patel · 2025 · Neurology and Therapy
  40. Integrating genome-wide and epigenome-wide associations for antipsychotic induced extrapyramidal side effects
    Kai Yao, Johan H. Thygesen, Siobhan K. Lock, Antonio F. Pardiñas, Antonia L. Pritchard, Israa Elbashir, Abdullah Lodhi, Zain-Ul-Abideen Ahmad, Michael C. O’Donovan, Michael John Owen et al. · 2025 · Psychopharmacology
  41. Reversible aripiprazole-induced tardive dyskinesia: a case series from Saudi Arabia and literature review
    Sultan M. Alshahrani, Lujain Mohammed Althagafi, Jameelah A. Saeedi, Lina Mohammed R. Aljohani, Aqeel Almarhoon, Ahmed S. Alyahya · 2026 · Frontiers in Psychiatry
  42. Initial physical health assessment for psychosis in Australia and New Zealand: 2026 recommendations
    Nicola Warren, Cullen O’Gorman, Frances Louise Dark, Susanna Every‐Palmer, Sean Halstead, Nicole Korman, Julia Lappin, Sharon Lawn, Brian N. O'Donoghue, Shuichi Suetani et al. · 2026 · Australian & New Zealand Journal of Psychiatry
  43. Predicting functional remission after antipsychotic discontinuation: a real-world study in schizophrenia
    Chang Lu, Yuke Dong, Zhaolin Zhai, Tianhao Gao, Mengyi Luo, Di Chang, Jing Chen, Jingxin Xue, Yuqing Zhao, Qiong Xiang et al. · 2026 · Psychological Medicine
  44. Prevalence and Associated Factors of Tardive Dyskinesia Among Psychiatric Patients on First-Generation Antipsychotics at Jimma University Specialized Hospital, Psychiatric Clinic, Ethiopia: Institution Based on A Cross-Sectional Study
    Tilahun Abdeta, Daniel Tolessa, Wondale Tsega · 2019 · Journal of Psychiatry and Psychiatric Disorders
  45. Drugs to Treat Schizophrenia and Psychosis (Dopamine Antagonists and Partial Agonists Other Than Clozapine)
    Robert Ali McCutcheon, Stephen John Kaar, Oliver David Howes · 2020 · Cambridge University Press eBooks
  46. Tics and Tourette syndrome
    Joseph J. Jankovic, Mark Hallett, Michael S. Okun, Cynthia Comella, Stanley Fahn, Jennifer G. Goldman · 2021 · Elsevier eBooks
  47. Tardive dyskinesia
    Zuleikha A Zalyalova · 2023 · S S Korsakov Journal of Neurology and Psychiatry
  48. Depression, Angststörungen, bipolare Störung, Schizophrenie, Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung
    Johanna Seifert, Stefan Bleich, Roland Seifert · 2023 · Springer eBooks
  49. Early Onset of Tardive Dyskinesia in an Antipsychotic-Naive Patient Treated With Low-Dose Cariprazine
    Konstantinos Tsamakis, Maria Pantazidi, Evangelos Alevyzakis, Dimitrios Tsiptsios, Christoph Mueller, Nikolaos Smyrnis, Emmanouil N. Rizos · 2024 · Journal of Clinical Psychopharmacology
  50. Treatment of tardive dyskinesia with clonazepam: A case report
    Bikram Chhetri, Dawa Gyeltshen · 2024 · Clinical Case Reports
  51. Antipsychotic Drugs
    Sarang Naresh Kshirsagar, Tapas Kumar Sahoo · 2024 · Springer eBooks
  52. Tardive Dyskinesia: Addressing the Challenges of an Iatrogenic Movement Disorder
    M. Nur E. Alam, Kashif Abbas, N. Usmani, Ali Mustafa · 2024 · International Journal of Biochemistry & Physiology
  53. Keeping up with the clinical advances: tardive dyskinesia
    Mazen T. Elkurd, Laxman B. Bahroo · 2019 · CNS Spectrums
  54. Drug-induced tardive dyskinesia
    Т. М. Оstroumova, Violetta Aleksandrovna Tolmacheva, Ol'ga Dmitrievna Ostroumova, Vladimir Anatolyevich Parfenov · 2020 · Neurology neuropsychiatry Psychosomatics
  55. Tardive Dyskinesia
    Kewal K. Jain · 2021 · Springer eBooks
  56. Medication-Induced Movement Disorders and Other Adverse Effects of Medication
    2022 · American Psychiatric Association Publishing eBooks
  57. Schizophrenia
    Robert Hudak, Jessica M. Gannon · 2022 · Current clinical practice
  58. Psychopharmacology
    Ronald T. Brown · 2023 · Elsevier eBooks
  59. Schizophrenia and Related Psychoses
    2025 · Wiley eBooks
  60. Stranded on Antipsychotics: Role of the Pediatric Clinician
    Rachel Ballard, Nia Heard‐Garris · 2019 · Clinical Pediatrics
  61. Unidad de Agudos: tratamientos antipsicóticos y de larga duración y criterios de calidad para la reducción de riesgos y mortalidad
    Vicente Tordera-Tordera · 2019 · Revisiones en Psicofarmacolog�a
  62. SHORT-TERM COST-EFFECTIVENESS OF SECOND-GENERATION LONG-ACTING INJECTABLE ANTIPSYCHOTICS AS COMPARED WITH ORAL ANTIPSYCHOTICS IN PREVENTING REHOSPITALIZATION OR TREATMENT SWITCH IN PATIENTS WITH SCHIZOPHRENIA
    Tyler Mantaian · 2019
  63. Computer-Aided Drug Design Against Dopamine D2 Receptor for Antischizophrenia Drug Development
    Dipankar Chaudhuri, Pradipta Bhattacharjee · 2020 · Lecture notes in bioengineering
  64. Mortality Risk of Antipsychotic Augmentation for Adult Depression
    Tobias Gerhard, T. Scott Stroup, Christoph Ulrich Correll, Soko Setoguchi, Brian L. Strom, Cecilia S. Huang, Zhiqiang Tan, Stephen Crystal, Mark Olfson · 2021 · FOCUS The Journal of Lifelong Learning in Psychiatry
  65. Treating schizophrenia: Should we emphasise ‘first do no harm’?
    Tom English, David Jonathan Castle · 2021 · Australian & New Zealand Journal of Psychiatry
  66. Olanzapine in the Treatment of Psychosis
    Gerd Laux · 2021 · Springer eBooks
  67. Part I: Interactive case: Adverse effects associated with antipsychotic therapy
    Kristen N. Gardner · 2021 · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY
  68. The tardive syndromes
    Joseph J. Jankovic, Mark Hallett, Michael S. Okun, Cynthia Comella, Stanley Fahn, Jennifer G. Goldman · 2021 · Elsevier eBooks
  69. Psychopharmakologische Grundlagen
    Thomas Köhler · 2020 · Springer eBooks
  70. What Might Not Be Learned in 4 Years of Psychiatry Residency Training
    Jeffrey J. Rakofsky · 2022 · Academic Psychiatry
  71. Antipsychotic-induced movement disorders: integrative review
    Maria Eduarda Antunes de Meira, Giuliano Mannrich, Nathalia Nahas Donatello, Daiana Cristina Salm · 2022 · REVISTA CIÊNCIAS EM SAÚDE
  72. Living in a Pharmacologically Imperfect World
    Joseph F. Goldberg · 2022 · The Journal of Clinical Psychiatry
  73. Behavioral Health Emergencies
    Karla Juvonen · 2022 · Physician Assistant Clinics
  74. Schizophrenie
    Steffen Moritz, Eva Carolin Krieger, Francesca Bohn, Julia Elmers, Ruth Veckenstedt · 2022 · Psychotherapie: Manuale
  75. Olanzapine in the Treatment of Psychosis
    Gerd Laux · 2022 · Springer eBooks
  76. Current treatment options in early-onset psychosis
    Anne Katrine Pagsberg, Marianne Melau · 2023 · Elsevier eBooks
  77. Şizofreni Tanılı Bireylerde Müzik Terapinin Etkisi
    Jiyan Baskın, Aydan Akk · 2024 · Journal of Health Sciences and Technologies
  78. Antipsychotic Drugs
    Shreedhar Paudel, Carol Lim, Oliver Freudenreich · 2024 · Elsevier eBooks
  79. Chapter 53. Treatment of Schizophrenia
    Mary F. Brunette, Jacob S. Ballon, Samantha A. Gnanasegaram, Agnieszka Kalinowski, William R. Keller, Jeffrey D. Reed, Doug Noordsy · 2024 · American Psychiatric Association Publishing eBooks
  80. Chapter 36. Management of Psychiatric Medication–Induced Movement Disorders
    Laura Marsh · 2024 · American Psychiatric Association Publishing eBooks
  81. Synopsis of Chemical and Drug-related Agents That Cause Movement Disorders
    Şükrü Alperen Korkmaz · 2024 · Springer eBooks
  82. Movement disorders related to drugs and toxins
    Zakiyah Aldaajani, Manal Abdulrazzak Badawi, Mona Talib Obaid · 2024 · International review of movement disorders
  83. Antipsychotic Drugs
    Shreedhar Paudel, Carol Lim, Oliver Freudenreich · 2024 · Elsevier eBooks
  84. Antipsychotika
    Gerhard Gründer · 2024 · Elsevier eBooks
  85. Current Treatments for Schizophrenia
    DONALD C. GOFF · 2025
  86. Use of Paliperidone Long-Acting Injections in Huntington's Disease
    Kamalakar Surineni, Vy Phuong Le, Kevin McKaughan, Namie Fotion · 2025 · Journal of Clinical Psychopharmacology
  87. Salience and executive network connectivity analyses in schizophrenia during emotional memory tasks
    Loïc Schollaert · 2025 · Cortica
  88. Trends in the Use of Antipsychotics for Off-Label Indications: Clinical and Ethical Considerations
    Muhammad Irfan Siddique, Shakeel Ahmad, Abida khan · 2025 · Biomedical & Pharmacology Journal
  89. Depression, Angststörungen, bipolare Störung, Schizophrenie, Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung
    Johanna Seifert, Stefan Bleich, Roland Seifert · 2026 · Springer eBooks
  90. Budget impact of xanomeline and trospium chloride for the treatment of adults with schizophrenia in the United States
    Aja Bjerke, Tyler Mantaian, Kristin Gillard, Matthew F. Sidovar, Jonathan Kowalski, Jeff Lee, Andrew Tunnicliffe · 2026 · Journal of Managed Care & Specialty Pharmacy
  91. What is Minimally Adequate Treatment of Psychosis and Should Duration of Inadequate Treatment be a Clinical and Research Target? A Perspective and State-of-the-Art Review
    Martin Osugo, Oliver David Howes · 2026 · Schizophrenia Bulletin
  92. Trends in antipsychotic and lithium use in Scandinavian countries from 2010 to 2023: a cross-country drug utilization study
    Nina Hanieh Hakimi, Michael Due Larsen, Ivana Bojanić · 2026 · BMC Psychiatry
  93. Assessing demographic and clinical characteristics and healthcare resource utilization of patients with schizophrenia with inadequate response to antipsychotic treatment
    Andre A. Hejazi, Morgan Bron, M. Mercedes Pérez-Rodríguez, Aida Attar, Maria Victoria Burgess, Erika Giraldo, Janelle Nimer, JOSEPH E. BISKUPIAK · 2026 · BMC Psychiatry
  94. Development of a discrete event simulation model for health economic evaluation of interventions for patients with schizophrenia
    Junwen Zhou · 2020
  95. VMAT2 Inhibitors for Tardive Dyskinesia: What Psychiatrists Should Know
    Arthur N. Westover, Jennifer Perez, Zena Patel, Manish K. Jha · 2026 · FOCUS The Journal of Lifelong Learning in Psychiatry
  96. Do Antipsychotics Work in People with Schizophrenia?
    Christoph Ulrich Correll · 2026 · Cambridge University Press eBooks
  97. Development of a patient decision aid prototype on the decision to continue, reduce or discontinue antipsychotic medication following remission of first-episode psychosis
    Laurent Béchard, Olivier Corbeil, Maxime Huot‐Lavoie, Olivier Roy, Sébastien Brodeur, Emmanuelle Bouchard, Joanne Martel, Natalie Pavey, Amélie M. Achim, Matthew Menear et al. · 2026 · BJPsych Open
  98. Cost-effectiveness analysis of xanomeline and trospium chloride for the treatment of adults with schizophrenia in the US
    Tyler Mantaian, Kristin Gillard, Jonathan Kowalski, Ken Kramer, Matthew F. Sidovar, Andrew J. Cutler · 2026 · Journal of Medical Economics
  99. Real-world patient characteristics, treatment patterns, and healthcare resource utilization and costs of tardive dyskinesia in Germany
    Christoph U. Correll, Jennifer S. Haas, Nayla Chaijale, Krzysztof Duma, Joachim Hipp, Di Zhang, Maurice T. Driessen · 2026 · Journal of Psychiatric Research
  100. Genetics of tardive dyskinesia: a review of progress over the past decade
    Clement C.H. Zai, Megana Thamilselvan, Francesca Chernous, Gwyneth C. Zai, Daniel J. Müller, James L. Kennedy, Arun K. Tiwari · 2026 · Pharmacogenomics